Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.
Pediatr Blood CancerJul 23, 2026 (epub)
Clinical ResearchOncology (Medical)
Przemysław Holko, Holger N Lode, Alberto Garaventa et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review analyzed the association between dinutuximab beta (DB) exposure and post-end-of-treatment survival in neuroblastoma patients using data from three clinical trials. Among 665 patients, increased cycles of DB treatment were linked to improved event-free survival (EFS) and overall survival (OS), with hazard ratios of 0.80 and 0.78 per cycle, respectively, both statistically significant (p < 0.001).
Key findings
- Each additional cycle of DB treatment decreased the hazard of an EFS event by 20%.
- Each additional cycle of DB treatment decreased the hazard of death by 22%.
- In a target-trial emulation, 5 cycles of DB significantly improved EFS (HR = 0.46) and OS (HR = 0.44).
- The median follow-up duration in the post-EOT cohort was 3.78 years.
Why it matters
Understanding the relationship between dinutuximab beta exposure and survival outcomes can guide clinicians in treatment planning and post-treatment risk assessment for neuroblastoma patients.